{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:15:20Z","timestamp":1776507320690,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41440-023-01318-7","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T05:01:57Z","timestamp":1685422917000},"page":"2048-2050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?"],"prefix":"10.1038","volume":"46","author":[{"given":"Daisuke","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mukoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl J Med. 2001;345:861\u20139.","journal-title":"N. Engl J Med"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl J Med. 2001;345:851\u201360.","journal-title":"N. Engl J Med"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","volume":"42","author":"E Mishima","year":"2019","unstructured":"Mishima E, Haruna Y, Arima H. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. Hypertens Res. 2019;42:469\u201382.","journal-title":"Hypertens Res"},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80:797\u2013811.","journal-title":"Drugs"},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G.","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1\u2013S276.","journal-title":"Kidney Int"},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","volume":"25","author":"AK Ahmed","year":"2010","unstructured":"Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transpl. 2010;25:3977\u201382.","journal-title":"Nephrol Dial Transpl"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41440-022-00877-5","volume":"45","author":"T Nakayama","year":"2022","unstructured":"Nakayama T, Morimoto K, Uchiyama K, Kusahana E, Washida N, Azegami T, et al. Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis. Hypertens Res. 2022;45:1018\u201327.","journal-title":"Hypertens Res"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41440-022-00902-7","volume":"45","author":"M Mukoyama","year":"2022","unstructured":"Mukoyama M, Kuwabara T. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use? Hypertens Res. 2022;45:1072\u20135.","journal-title":"Hypertens Res"},{"key":"1318_CR12","doi-asserted-by":"publisher","unstructured":"Nakayama T, Mitsuno R, Azegami T, Sato Y, Hayashi K, Itoh H. A systematic review and meta-analysis of the clinical impact of stopping renin-angiotensin system inhibitor in patients with chronic kidney disease. Hypertens Res. 2023. https:\/\/doi.org\/10.1038\/s41440-023-01260-8.","DOI":"10.1038\/s41440-023-01260-8"},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N. Engl J Med. 2022;387:2021\u201332.","journal-title":"N. Engl J Med"},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"604017","DOI":"10.3389\/fphar.2021.604017","volume":"12","author":"Y Xu","year":"2021","unstructured":"Xu Y, Chen Y, Zhao JW, Li C, Wang AY. Effect of angiotensin-neprilysin versus renin-angiotensin system inhibition on renal outcomes: a systematic review and meta-analysis. Front Pharm. 2021;12:604017.","journal-title":"Front Pharm"},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl J Med. 2014;371:993\u20131004.","journal-title":"N. Engl J Med"},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017;2:79\u201385.","journal-title":"JAMA Cardiol"},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl J Med. 2019;381:1995\u20132008.","journal-title":"N. Engl J Med"},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L, Kristensen SL, Bengtsson O, Bohm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9:254\u201364.","journal-title":"JACC Heart Fail"},{"key":"1318_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced. J Am Coll Cardiol. 2021;77:1397\u2013407.","journal-title":"J Am Coll Cardiol"},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33:225\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460\u201370.","journal-title":"Circulation"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01318-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T23:10:03Z","timestamp":1691363403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01318-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01318-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}